Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Plasma proteomics detects hyperlipoprotein A in a patient with recurrent lipomas.

JAAD case reports·2026

Same author

Amelioration of Dominant Dystrophic Epidermolysis Bullosa Ulceration by Combination Gentian Violet and Trichloroacetic Acid Therapy.

Journal of drugs in dermatology : JDD·2026

Same author

TPL2 Promotes Gastric Cancer Progression and Chemoresistance Through a Hypoxia-Induced Positive Feedback Loop with PPARδ.

International journal of biological sciences·2025

Same author

Successful Treatment of Sacral Pressure Injury With ACU-D1

Journal of drugs in dermatology : JDD·2025

Same author

The Carcinogenesis of the Human Scalp: An Immunometabolic-Centered View.

International journal of molecular sciences·2024

Same author

Dibenzolium induces apoptosis and inhibits epithelial-mesenchymal transition (EMT) in bladder cancer cell lines.

Scientific reports·2024

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Efficacy of rapamycin in scleroderma: a case study.

Levi Fried¹, Robert S Kirsner, Sulochana Bhandarkar

¹Department of Dermatology, Emory University School of Medicine, Atlanta, GA 30322, USA.

Lymphatic Research and Biology

|October 28, 2008

Summary

Rapamycin shows promise for treating scleroderma, an autoimmune disorder. This study observed rapid improvements in skin stiffness and mobility in a patient, suggesting rapamycin

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Related Experiment Videos

Last Updated: Jun 28, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Area of Science:

Immunology
Dermatology
Pharmacology

Background:

Scleroderma is an autoimmune disease characterized by fibrosis.
Current theories suggest endothelial mesenchymal transformation, mediated by TGF-beta, drives scleroderma.
This process leads to excessive collagen synthesis and tissue stiffening.

Observation:

In vitro studies indicated rapamycin might counteract collagen synthesis.
Rapamycin exhibits antiangiogenic and wound healing inhibitory properties.
These characteristics prompted its investigation in a scleroderma patient.

Findings:

Rapamycin administration resulted in rapid improvement of skin stiffness.
Enhanced skin mobility was observed following rapamycin treatment.
The patient experienced significant symptom relief.

Implications:

These findings support rapamycin as a potential therapeutic agent for scleroderma.
Further clinical trials are warranted to validate rapamycin's efficacy.
Rapamycin may also benefit other fibrotic disorders.